WS Investor
08 Apr 2026, 19:30
Becton, Dickinson and Company announced CE Mark approval for its Liverty™ TIPS Stent Graft, introducing a next-generation treatment option for patients with portal hypertension across the European Union.
The device is designed to support patients with advanced liver disease, including cirrhosis-related complications, by improving blood flow through transjugular intrahepatic portosystemic shunt (TIPS) procedures. Its adjustable diameter (6–10 mm) allows physicians to tailor treatment to individual patient needs, enhancing precision and potential long-term outcomes.
Clinical data from the ARCH trial demonstrated the device’s safety and effectiveness and will be presented at the Society of Interventional Radiology’s 2026 annual meeting. The stent graft features a flexible, self-expanding structure and advanced materials aimed at improving placement accuracy and durability.
The approval expands treatment options in Europe for a condition affecting millions globally, while the device remains under investigational use in the United States.
PRNewswire
The device is designed to support patients with advanced liver disease, including cirrhosis-related complications, by improving blood flow through transjugular intrahepatic portosystemic shunt (TIPS) procedures. Its adjustable diameter (6–10 mm) allows physicians to tailor treatment to individual patient needs, enhancing precision and potential long-term outcomes.
Clinical data from the ARCH trial demonstrated the device’s safety and effectiveness and will be presented at the Society of Interventional Radiology’s 2026 annual meeting. The stent graft features a flexible, self-expanding structure and advanced materials aimed at improving placement accuracy and durability.
The approval expands treatment options in Europe for a condition affecting millions globally, while the device remains under investigational use in the United States.
PRNewswire
